Oregovomab

Drug Profile

Oregovomab

Alternative Names: Anti CA125 Mab oregovomab; B43.13; Mab B43.13; Monoclonal antibody B43.13; OvaRex

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer
  • Phase I/II Peritoneal cancer

Most Recent Events

  • 24 May 2017 OncoQuest plans a phase I trial for Ovarian cancer (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03162562)
  • 22 Feb 2017 Phase-I/II clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Singapore (IV) (NCT03100006)
  • 22 Feb 2017 Phase-I/II clinical trials in Peritoneal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Singapore (IV) (NCT03100006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top